Oncimmune has signed a collaboration with Genentech, a member of the Roche Group, to use its NavigAID panel to profile samples from Genentech’s rheumatology clinical trials, initially focused on Systemic Lupus Erythematosus. If this initial project is successful, it could pave the way for more substantial and lucrative follow-on projects in rheumatology, as was seen in oncology with Roche in May 2020. This is Oncimmune’s first ImmunoINSIGHTS contract in autoimmune disease, and highlights the pot ....
23 Sep 2020
Latest pharma contract 1st to explore platform in autoimmune diseases
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Latest pharma contract 1st to explore platform in autoimmune diseases
Oncimmune Holdings Plc (ONC:LON) | 26.4 0 0.0% | Mkt Cap: 19.6m
- Published:
23 Sep 2020 -
Author:
Edward Thomason -
Pages:
3
Oncimmune has signed a collaboration with Genentech, a member of the Roche Group, to use its NavigAID panel to profile samples from Genentech’s rheumatology clinical trials, initially focused on Systemic Lupus Erythematosus. If this initial project is successful, it could pave the way for more substantial and lucrative follow-on projects in rheumatology, as was seen in oncology with Roche in May 2020. This is Oncimmune’s first ImmunoINSIGHTS contract in autoimmune disease, and highlights the pot ....